ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry MomentumSARASOTA, Fla.

Oragenics’ lead drug candidate, ONP-002, is a neuroprotective, anti-inflammatory compound delivered intranasally for the treatment of mild traumatic brain injury (mTBI) or concussion.

Oragenics (OGEN), provided shareholders with an update on its strategic and financial progress for the first quarter of 2025. The Company has ...

ONP-002 is an intranasal therapeutic being developed for concussion and is designed to ... clinical trial and submitted the Investigator’s Brochure to regulatory authorities in Australia.

ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation ... production for the Phase IIa clinical trial and submitted the Investigator's Brochure to regulatory ...

aiming to transform concussion treatment by enabling faster, more targeted care. Clinical Trial Advancements: Submitted the Investigator's Brochure (IB) for the Phase IIa clinical trial in ...

Almost two-thirds of the claimants in a concussion lawsuit against rugby league authorities showed symptoms of chronic traumatic encephalopathy, according to documents seen by the BBC. The ...

Lake Tahoe is unlike other natural resources when it comes to management and stewardship. The 500-mile watershed spans two states, five counties and a city. More than 50 years ago, Congress ...

Concussions Slow Brain Activity of High School Football Players Nov. 27, 2024 — A new study of high school football players found that concussions affect an often-overlooked but important brain ...

Liquidia Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat ...

As of 9:38:33 a.m. EDT. Market Open. Loading Chart for OGEN ...